A Phase IIb study of STN1014100 ophthalmic solution in patients with dry eye

A Phase IIb, double-masked, randomized, multi-center, placebo-controlled, parallel-group study of STN1014100 ophthalmic solution in patients with dry eye

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031250105

Enrollment

400

Registered

2025-05-16

Start date

2025-05-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye

Interventions

Group 1: STN1014100 or placebo, 1 drop, once daily Group 2: STN1014100 or placebo, 1 drop, twice daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - 18 years of age or older - Male or Female - Both eyes diagnosed with dry eye

Exclusion criteria

Exclusion criteria: - Any corneal and conjunctival abnormalities or other diseases other than dry eye affecting the ocular surface - Having any eye disease requiring treatment other than dry eye. -Anatomically and functionally abnormal eyelids (e.g. Eyelid closure failure) -The principal investigator or a sub-investigator judges it inappropriate as the subject of this clinical trial.

Design outcomes

Primary

Measure	Time frame
Change from baseline in dry eye signs	—

Contacts

Public ContactKoji Oka

Santen pharmaceutical co.,ltd

clinical@santen.co.jp+81-6-4802-9341

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026